SCHEMBL9823334

SCHEMBL9823334

O=C(O)c1csc(-c2ccccc2O)n1

nearest known ligand 0.73

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HTR2B P41595 2/20 0.73
ACHE P22303 2/20 0.63
KDM4E B2RXH2 1/20 0.57
HPGDS O60760 1/20 0.55
CASP3 P42574 1/20 0.53
RAB9A P51151 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
SENP8 Q96LD8 1/20 0.53
SENP7 Q9BQF6 1/20 0.53
SENP6 Q9GZR1 1/20 0.53
ALDH1A1 P00352 1/20 0.53
PTGER1 P34995 2/20 0.51
CYP19A1 P11511 1/20 0.50
HDAC1 Q13547 1/20 0.47
HDAC8 Q9BY41 1/20 0.47
HDAC6 Q9UBN7 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15602692 0.87 HTR2B (0.56) HTR2BACHEKDM4EHPGDSCASP3
Pulicatins F SCHEMBL12469099 0.85 HTR2B (1.00) HTR2BACHECASP3RAB9ASMN1; SMN2
SCHEMBL9823114 0.83 ACHE (0.60) HTR2BACHEKDM4EHPGDSALDH1A1
SCHEMBL2693403 0.83 ACHE (0.63) HTR2BACHEKDM4EHPGDSALDH1A1
SCHEMBL3536997 0.81 ACHE (0.66) HTR2BACHEKDM4EHPGDSALDH1A1
SCHEMBL2691637 0.81 ACHE (0.61) HTR2BACHEKDM4EHPGDSRAB9A
SCHEMBL2545992 0.81 ACHE (0.61) HTR2BACHEKDM4EHPGDSALDH1A1
SCHEMBL6183496 0.81 ACHE (0.66) HTR2BACHEKDM4EHPGDSALDH1A1
SCHEMBL6251863 0.81 ACHE (0.61) HTR2BACHEKDM4EHPGDSALDH1A1
SCHEMBL26320404 0.81 ACHE (0.61) HTR2BACHEKDM4EHPGDSALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0033151-B1 HYDROXYPHENYL-THIAZOLE-THIAZOLINE AND -THIAZOLIDINE CARBOXYLIC ACIDS, PROCESS FOR THEIR PREPARATION AND THESE COMPOUNDS FOR USE IN INFLUENCING THE COLLAGEN METABOLISM HOECHST AKTIENGESELLSCHAFT (DE) 1984-05-02 EP claimed
US-20260026508-A1 Seed Treatment Formulations and Methods of Use PUNA BIO CORP (US) 2026-01-29 US disclosed
WO-2023170024-A1 CAMK2 MODULATORS AND THEIR USE IN MEDICINE UNIVERSITY OF COPENHAGEN (DK) 2023-09-14 WO disclosed
US-11421223-B2 Processes and host cells for genome, pathway, and biomolecular engineering ENEVOLV, INC. (US) 2022-08-23 US disclosed
US-20190309289-A1 PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING ENEVOLV, INC. 2019-10-10 US disclosed
US-10370654-B2 Processes and host cells for genome, pathway, and biomolecular engineering ENEVOLV, INC. (US) 2019-08-06 US disclosed
US-20180320170-A1 PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING ENEVOLV, INC. 2018-11-08 US disclosed
US-9944925-B2 Processes and host cells for genome, pathway, and biomolecular engineering ENEVOLV, INC. 2018-04-17 US disclosed
US-9751847-B2 Methods and compositions related to neuroactive thiazoline compounds UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) 2017-09-05 US disclosed
US-9751847-B2 Methods and compositions related to neuroactive thiazoline compounds UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) 2017-09-05 US disclosed
US-20160186168-A1 PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING ENEVOLV, INC. 2016-06-30 US disclosed
EP-3027754-A1 PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING enEvolv, Inc. (US) 2016-06-08 EP disclosed
WO-2015017866-A1 PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING ENEVOLV, INC. (US) 2015-02-05 WO disclosed
US-20140018400-A1 METHODS AND COMPOSITIONS RELATED TO NEUROACTIVE THIAZOLINE COMPOUNDS UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) 2014-01-16 US disclosed
US-20140018400-A1 METHODS AND COMPOSITIONS RELATED TO NEUROACTIVE THIAZOLINE COMPOUNDS UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) 2014-01-16 US disclosed
EP-0262873-B1 N-TETRAZOLYL THIAZOLECARBOXAMIDE DERIVATIVES AND THEIR USE SAWAI PHARMACEUTICAL CO., LTD. (JP) 1991-08-21 EP disclosed
US-4879295-A ANTIALLERGENS SAWAI PHARMACEUTICAL CO., LTD. (JP) 1989-11-07 US disclosed
EP-0262873-A1 N-tetrazolyl thiazolecarboxamide derivatives and their use SAWAI PHARMACEUTICAL CO., LTD. (JP) 1988-04-06 EP disclosed
EP-0033151-B1 HYDROXYPHENYL-THIAZOLE-THIAZOLINE AND -THIAZOLIDINE CARBOXYLIC ACIDS, PROCESS FOR THEIR PREPARATION AND THESE COMPOUNDS FOR USE IN INFLUENCING THE COLLAGEN METABOLISM HOECHST AKTIENGESELLSCHAFT (DE) 1984-05-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140018400-A1 METHODS AND COMPOSITIONS RELATED TO NEUROACTIVE THIAZOLINE COMPOUNDS TACR2, TACR3, TACR1 HTR2B 58/4885ACHE 167/4885KDM4E 4513/4885
US-20260026508-A1 Seed Treatment Formulations and Methods of Use PGLS, GNE, GALE HTR2B 4667/4885ACHE 386/4885KDM4E 80/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.